TD Asset Management
OCUL icon

TD Asset Management’s Ocular Therapeutix OCUL Stock Holding History

TD Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Sell
229,800
-8,200
-3% -$74.3K ﹤0.01% 944
2026
Q1 		$2.02M Buy
+238,000
New +$2.27M ﹤0.01% 964
2025
Q1 		– Sell
-60,000
Closed -$512K – 1253
2024
Q4 		$512K Sell
60,000
-52,800
-47% -$515K ﹤0.01% 1184
2024
Q3 		$979K Hold
112,800
– – ﹤0.01% 1188
2024
Q2 		$772K Buy
112,800
+32,400
+40% +$200K ﹤0.01% 1205
2024
Q1 		$732K Buy
+80,400
New +$571K ﹤0.01% 1237

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TD Asset Management's OCUL Position: Q2 2026 in Review

TD Asset Management reduced its Ocular Therapeutix (OCUL) stake by 3.4% in Q2 2026, selling an estimated $74.3K and leaving 229,800 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #944.

TD Asset Management first reported a position in OCUL in Q1 2024 and has held it in 6 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • TD Asset Management held 229,800 shares of Ocular Therapeutix worth $2.26M as of Q2 2026.
  • TD Asset Management sold 8,200 Ocular Therapeutix shares in Q2 2026, an estimated $74.3K.
  • Ocular Therapeutix made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #944 holding.
  • TD Asset Management first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 6 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.